Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.

García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA; FarmaPEG Study Group.

BMC Pharmacol. 2010 Nov 23;10:15. doi: 10.1186/1471-2210-10-15.

2.

Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers.

Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Ducongé J, Correa-Fernandez A, Olivera-Ruano L, Lopez-Saura P.

Drugs R D. 2004;5(5):271-80.

PMID:
15357626
3.

A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.

Zheng L, Li MP, Gou ZP, Wang Y, Xu N, Cai YM, Luo H.

Br J Clin Pharmacol. 2015 Apr;79(4):650-9. doi: 10.1111/bcp.12528.

4.

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.

García-Vega Y, García-García I, Collazo-Caballero SE, Santely-Pravia EE, Cruz-Ramírez A, Tuero-Iglesias AD, Alfonso-Alvarado C, Cabrera-Placeres M, Castro-Basart N, Duncan-Roberts Y, Carballo-Treto TI, Soto-Matos J, Izquierdo-Toledo Y, Vázquez-Blomquist D, García-Iglesias E, Bello-Rivero I.

BMC Pharmacol Toxicol. 2012 Dec 28;13:20. doi: 10.1186/2050-6511-13-20.

5.

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.

Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G.

J Clin Pharmacol. 2012 Jun;52(6):798-808. doi: 10.1177/0091270011407068. Epub 2011 Jun 16. Erratum in: J Clin Pharmacol. 2012 Sep;52(9):NP4-5.

PMID:
21680782
6.

Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.

De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DG.

J Interferon Cytokine Res. 2008 Feb;28(2):113-22. doi: 10.1089/jir.2007.0073.

PMID:
18279106
7.

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.

Bruno R, Sacchi P, Scagnolari C, Torriani F, Maiocchi L, Patruno S, Bellomi F, Filice G, Antonelli G.

Aliment Pharmacol Ther. 2007 Aug 1;26(3):369-76.

8.

Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.

Brennan BJ, Xu ZX, Grippo JF.

Clin Ther. 2012 Sep;34(9):1883-91. doi: 10.1016/j.clinthera.2012.07.003. Epub 2012 Aug 1.

PMID:
22858176
10.

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM.

Br J Clin Pharmacol. 1998 Dec;46(6):563-70.

11.

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S.

Clin Pharmacol Ther. 2000 Nov;68(5):556-67.

PMID:
11103758
12.

Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.

Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC.

Int J Pharm. 2006 Feb 17;309(1-2):87-93. Epub 2006 Jan 9.

PMID:
16406701
13.

Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study.

Patel TB, Pequignot E, Parker SH, Leavitt MC, Greenberg HE, Kraft WK.

Int J Clin Pharmacol Ther. 2007 Mar;45(3):161-8.

PMID:
17416111
14.

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L.

J Clin Oncol. 2001 Mar 1;19(5):1312-9.

PMID:
11230473
15.

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.

Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C.

J Pharmacol Exp Ther. 2002 Nov;303(2):540-8.

16.

Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.

Cai Y, Zhang Z, Fan K, Zhang J, Shen W, Li M, Si D, Luo H, Zeng Y, Fu P, Liu C.

Regul Pept. 2012 Jan 10;173(1-3):74-81. doi: 10.1016/j.regpep.2011.09.008. Epub 2011 Oct 8.

PMID:
21985916
18.

Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.

Foster GR.

Expert Opin Pharmacother. 2003 May;4(5):685-91. Review.

PMID:
12739994
19.

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.

Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H.

Clin Cancer Res. 2005 Sep 1;11(17):6247-55.

20.

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, Negrier S, Ernst S, Siebels M, Ginsberg M, Rittweger K, Hooftman L.

Ann Oncol. 2002 Nov;13(11):1799-805.

PMID:
12419754

Supplemental Content

Support Center